Bendamustine combined with anti-CD20 monoclonal antibody in the first-line treatment of older patients with indolent B-cell non-Hodgkin lymphoma: a multicenter retrospective study
10.3760/cma.j.cn121090-20241227-00597
- VernacularTitle:苯达莫司汀联合抗CD20单抗一线治疗老年惰性B细胞非霍奇金淋巴瘤的多中心回顾性研究
- Author:
Shuchao QIN
1
;
Yi MIAO
;
Zhaoliang ZHANG
;
Jie ZHANG
;
Yuye SHI
;
Yuqing MIAO
;
Weiying GU
;
Weicheng ZHENG
;
Zhuxia JIA
;
Guoqiang LIN
;
Haiwen NI
;
Xiaohong XU
;
Min XU
;
Xiaoyan XIE
;
Ling WANG
;
Yun ZHUANG
;
Wei ZHANG
;
Ping LIU
;
Jianyong LI
;
Wenyu SHI
Author Information
1. 南京医科大学第一附属医院，江苏省人民医院血液科，南京 210029
- Publication Type:Journal Article
- Keywords:
Bendamustine hydrochloride;
Elderly;
B-cell indolent lymphoma;
First-line therapy
- From:
Chinese Journal of Hematology
2025;46(9):820-826
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of bendamustine combined with anti-CD20 monoclonal antibody in the first-line treatment of older patients with indolent B-cell non-Hodgkin lymphoma (B-iNHL) .Methods:The clinical data of 159 patients with B-iNHL enrolled in 16 hospitals from Jiangsu Cooperative Lymphoma Group from December 1, 2019, to April 20, 2024, were analyzed for regimen efficacy and safety. Bendamustine plus rituximab (BR) and bendamustine plus obinutuzumab (BG) were administered to 139 (87.4% ) and 20 (12.6% ) patients, respectively.Results:Among the 159 patients, 101 (63.5% ) were male and 58 (36.5% ) were female, with a median age of 69 years (range: 60–84). Efficacy could be assessed in 138 (86.8% ) patients. The efficacy assessment demonstrated that the overall response rate was 92.0% with complete and partial remissions in 75 (54.3% ) and 52 (37.7% ) cases, respectively. With a median follow-up of 24 months (range: 4–64), the progression-free survival rate was (87.5 ± 3.0) % and the overall survival rate was (83.2 ± 3.3) %. Of the 27 patients who died, 6 (22.2% ) died due to disease progression. The mean applied dose of bendamustine per cycle was 73.0 (50.8–89.7) mg/m 2 per day, administered on days 1 and 2. Adverse events of grade 3 or higher were reported in 53 (33.3% ) patients, with infection (30 cases,18.9% ) and neutropenia (24 cases, 15.1% ) demonstrating the highest incidence. Conclusion:Bendamustine combined with anti-CD20 monoclonal antibody demonstrated good efficacy and is well-tolerated in the first-line treatment of elderly patients with B-iNHL.
